The treatment of chronic progressive multiple sclerosis with cladribine.
about
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineEvaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisCladribine tablets for the treatment of relapsing-remitting multiple sclerosisSystematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?Development of oral immunomodulatory agents in the management of multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesRecent developments in multiple sclerosis therapeuticsRecent developments in drug therapy for multiple sclerosis.Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisThe natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disabilityTherapeutic developments in multiple sclerosis.New oral disease-modifying therapies for multiple sclerosis.Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis.Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tabletsToxicities of immunosuppressive treatment of autoimmune neurologic diseases.Chemotherapeutics in the treatment of multiple sclerosis.Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents.Cladribine: not just another purine analogue?Oral disease-modifying therapies for multiple sclerosis.Emerging therapies for treatment of multiple sclerosisIntense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.Cladribine for multiple sclerosis: review and current status.Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine.More immunotherapy for multiple sclerosis.Immunosuppressive agents in multiple sclerosis.Update on the treatment options for multiple sclerosis.Immunomodulatory drug treatment in multiple sclerosis.Managing MS in a changing treatment landscape.Emerging oral drugs for relapsing-remitting multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects.Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.An update on cladribine for relapsing-remitting multiple sclerosis.Both cladribine and alemtuzumab may effect MS via B-cell depletionSuccessful treatment of lupus with fludarabine.
P2860
Q24597369-6A683529-4606-4FA5-A5D3-9151BB4CEBABQ26782408-9D4B7E98-A0BD-4F45-B21B-D22D39177499Q27000269-01EBE96B-C561-46EC-8E26-527D6DA0BD21Q28281816-00714F2B-6233-4179-AC80-7529DB9D03AFQ28363134-BE4650AB-E07B-4CC1-8AA0-1CDC5FCDC26CQ28388704-ABAFE7D8-A9F3-4C3F-8658-2A5983124DBEQ29030703-7421EC6A-82D7-4917-9420-D4279D2A2489Q30962193-A813CD2C-F084-452E-9C44-F398B555FEF0Q33639891-3DBA8804-087B-4A34-9AEC-D2845CDB44C7Q33644812-B86F206D-9B0B-48DF-BAD0-6168BEBF7580Q33802186-8A9AF7C1-DEDF-49F0-85EA-8E66866F5BBAQ33944200-94D1A96F-7FE3-4FC3-86BE-8445C32F1B2FQ34074776-FB17DD81-8D72-4CAB-91DD-C6AE5C6551A0Q34076398-7407EF0B-85E4-42E2-BEB4-204FB44C3C98Q34100842-EFB084E2-D4A5-4E7F-804F-EAA87299266EQ34133316-9B44B2DE-A6B4-4415-9F13-04197418CEAEQ34257903-C3DCB167-D986-4231-93A0-68F6C730A5F2Q34409536-36FA4A21-F3B4-48D5-BBFA-8412911B1490Q34714866-73D7A8D7-51CD-4656-86EA-1C4E3A1BEEAEQ34992373-E1A1D213-0771-402B-AD3A-9F89B22724A1Q34996562-4EDE7A2C-3576-4376-85DC-D29B5003818CQ35557390-6F916C7A-2AF5-43D8-BFB4-AE8917AB395AQ36226307-F0559287-3628-4A56-991A-9C31FB83989FQ36307847-CD0A6139-02CB-45F6-A9CA-A707A7B1FED7Q36353053-7FC4FF6D-6982-45C0-87BB-C40B163860C3Q36648175-3BA9386B-0C8F-40AB-A5ED-F21B686EC924Q36748692-04C28E8F-C9C1-476B-AF52-54C1731985D6Q36896700-6315B394-8189-4678-AC23-B0539D3092F2Q36963189-31BDFE4E-F52D-4798-8A3F-61000991485DQ37729045-829A67F6-640B-4422-B875-4F62B13A6E23Q37785554-509A9040-3CBF-4A6C-A12B-F2499C193313Q37857752-671D3808-E99D-49B7-ABFF-8F697B7894C1Q37965547-B0279F6F-C561-479B-BBBB-9C418FA402B8Q38083041-519D40BB-342B-4787-A100-42154ED1928FQ38101003-D91D59F4-DFE8-4C56-9DFD-E1E205DFF624Q38372016-9C476984-81FF-4149-B4D0-1A28788A5526Q38534132-24CD342C-EC42-4DC7-A909-44CC1876DCA0Q38600051-5EF85116-0006-492F-A88D-C945B996A352Q38720045-8E17E92A-31BC-4314-97DE-CD36C0085283Q40628909-ADF883D4-596C-432E-8FB3-B900EE9894AD
P2860
The treatment of chronic progressive multiple sclerosis with cladribine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The treatment of chronic progressive multiple sclerosis with cladribine.
@en
The treatment of chronic progressive multiple sclerosis with cladribine.
@nl
type
label
The treatment of chronic progressive multiple sclerosis with cladribine.
@en
The treatment of chronic progressive multiple sclerosis with cladribine.
@nl
prefLabel
The treatment of chronic progressive multiple sclerosis with cladribine.
@en
The treatment of chronic progressive multiple sclerosis with cladribine.
@nl
P2093
P2860
P356
P1476
The treatment of chronic progressive multiple sclerosis with cladribine.
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.4.1716
P407
P577
1996-02-01T00:00:00Z